Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline
2014 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline
Bandelow, B.; Bauer, M.; Vieta, E.; El-Khalili, N.; Gustafsson, U.; Earley, W. R. & Eriksson, H. (2014)
The World Journal of Biological Psychiatry, 15(2) pp. 155-166. DOI: https://doi.org/10.3109/15622975.2013.842654
Documents & Media
Details
- Authors
- Bandelow, Borwin; Bauer, Michael; Vieta, Eduard; El-Khalili, Nizar; Gustafsson, Urban; Earley, Willie R.; Eriksson, Hans
- Abstract
- Objectives. To evaluate quetiapine XR in patients with anxious depression, as defined by HAM-A total and HAM-D anxiety/somatisation factor scores. Methods. Post hoc analyses of pooled data from two 6-week, double-blind, randomised, placebo-controlled studies of adjunctive quetiapine XR (150 or 300 mg/day) in patients with MDD and inadequate response to antidepressants. Patients were stratified in a primary analysis using HAM-A (HAM-A total score at baseline >= 20 ["high"] or <20 ["low"]) and a secondary analysis using HAM-D (anxious depression defined as HAM-D anxiety/somatisation factor score >= 7). Outcomes included change in MADRS total score. Results. In patients with high anxiety levels (HAM-A total score >= 20), reductions in MADRS total score were -15.20 (P = 0.122) and -15.92 (P < 0.05) for quetiapine XR 150 and 300 mg/day, respectively, vs. placebo (-13.49). In patients with low levels of anxiety (HAM-A total score < 20), both quetiapine XR doses (P < 0.001) improved MADRS total scores vs. placebo. In the secondary analysis, quetiapine XR 150 (P < 0.01) and 300 mg/day (P < 0.001) improved MADRS total score vs. placebo in patients with HAM-D anxiety/somatisation factor score >= 7. Conclusions. Adjunct quetiapine XR demonstrates efficacy in patients with anxious and non-anxious depression, assessed using HAM-A total score, and anxious depression assessed using HAM-D anxiety/somatisation factor score.
- Issue Date
- 2014
- Status
- published
- Publisher
- Informa Healthcare
- Journal
- The World Journal of Biological Psychiatry
- ISSN
- 1814-1412; 1562-2975
- Sponsor
- AstraZeneca [D1448C00006, D1448C00007]